[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
R Ella, KM Vadrevu, H Jogdand, S Prasad… - The Lancet Infectious …, 2021 - thelancet.com
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …
R Ella, S Reddy, H Jogdand, V Sarangi… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
[PDF][PDF] Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
B Ganneru, H Jogdand, VK Daram, D Das, NR Molugu… - Iscience, 2021 - cell.com
We report the development and evaluation of safety and immunogenicity of a whole virion
inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (…
inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (…
[HTML][HTML] Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
KM Vadrevu, B Ganneru, S Reddy, H Jogdand… - Scientific reports, 2022 - nature.com
This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised …
KM Vadrevu, S Reddy, H Jogdand… - The Lancet Infectious …, 2022 - thelancet.com
Background Despite having milder symptoms than adults, children are still susceptible to
and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to …
and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to …
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of …
R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru… - medRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
Evaluation of safety and immunogenicity of an adjuvanted, TH-1 skewed, whole virion InactivatedSARS-CoV-2 vaccine-BBV152
B Ganneru, H Jogdand, VK Dharam, NR Molugu… - BioRxiv, 2020 - biorxiv.org
We report the development and evaluation of safety and immunogenicity of a whole virion
inactivated SARS-COV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), …
inactivated SARS-COV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), …
A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152
R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy… - MedRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double-…
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double-…
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study
KM Vadrevu, S Reddy, H Jogdand, B Ganneru, N Mirza… - medRxiv, 2021 - medrxiv.org
Background We assessed the safety, reactogenicity, and immunogenicity of BBV152 in an
open-label age de-escalation study in three age cohorts of children from 18 years of age …
open-label age de-escalation study in three age cohorts of children from 18 years of age …
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
KM Vadrevu, B Ganneru, S Reddy, H Jogdand, D Raju… - MedRxiv, 2022 - medrxiv.org
Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …